ZA200805839B - Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of Alzheimer's disease via GABA receptors - Google Patents

Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of Alzheimer's disease via GABA receptors

Info

Publication number
ZA200805839B
ZA200805839B ZA200805839A ZA200805839A ZA200805839B ZA 200805839 B ZA200805839 B ZA 200805839B ZA 200805839 A ZA200805839 A ZA 200805839A ZA 200805839 A ZA200805839 A ZA 200805839A ZA 200805839 B ZA200805839 B ZA 200805839B
Authority
ZA
South Africa
Prior art keywords
isoxazol
imidazo
alzheimer
aryl
treatment
Prior art date
Application number
ZA200805839A
Other languages
English (en)
Inventor
Buettelmann Bernd
Han Bo
Knust Henner
Thomas Andrew
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37965110&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200805839(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200805839B publication Critical patent/ZA200805839B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
ZA200805839A 2006-01-17 2008-07-03 Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of Alzheimer's disease via GABA receptors ZA200805839B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06100426 2006-01-17

Publications (1)

Publication Number Publication Date
ZA200805839B true ZA200805839B (en) 2009-09-30

Family

ID=37965110

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200805839A ZA200805839B (en) 2006-01-17 2008-07-03 Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of Alzheimer's disease via GABA receptors

Country Status (15)

Country Link
US (1) US7585874B2 (fr)
EP (1) EP1979350A1 (fr)
JP (1) JP4913157B2 (fr)
KR (1) KR101062583B1 (fr)
CN (1) CN101370807B (fr)
AR (1) AR059016A4 (fr)
AU (1) AU2007207053B2 (fr)
BR (1) BRPI0706560A2 (fr)
CA (1) CA2636112A1 (fr)
IL (1) IL192636A0 (fr)
NO (1) NO20082956L (fr)
RU (1) RU2426732C2 (fr)
TW (1) TWI338691B (fr)
WO (1) WO2007082806A1 (fr)
ZA (1) ZA200805839B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200904477B (en) 2006-11-27 2010-09-29 Lundbeck & Co As H Heteroaryl amide derivatives
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
WO2009000662A1 (fr) * 2007-06-22 2008-12-31 F. Hoffmann-La Roche Ag Dérivés d'isoxazole-imidazole
CN101889010B (zh) 2007-12-04 2012-12-05 弗·哈夫曼-拉罗切有限公司 异*唑-吡啶衍生物
RU2502737C2 (ru) 2009-09-24 2013-12-27 Ф. Хоффманн-Ля Рош Аг Производные имидазопиридина или имидазопиримидина в качестве ингибиторов фосфодиэстеразы 10а
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
PT2571503E (pt) 2010-05-14 2015-04-29 Dana Farber Cancer Inst Inc Composições e a sua utilização no tratamento de neoplasia, doença inflamatória e outros distúrbios
EP2571875A4 (fr) 2010-05-14 2013-10-30 Dana Farber Cancer Inst Inc Compositions contraceptives pour les hommes et procédés d'utilisation associés
BR112012029057A2 (pt) 2010-05-14 2020-10-13 Dana-Farber Cancer Institute, Inc. composições e métodos de tratamento de leucemia
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
CA2884956A1 (fr) 2012-11-29 2014-06-05 F. Hoffmann-La Roche Ag Derives d'imidazopyridine
US9714946B2 (en) 2013-03-14 2017-07-25 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
DK2991983T3 (en) * 2013-04-29 2017-05-08 Hoffmann La Roche 2-PHENYL OR 2-HETARYLIMIDAZOLE [1,2-a] PYRIDINE DERIVATIVES
RU2016105108A (ru) * 2013-07-25 2017-08-30 Дана-Фарбер Кэнсер Инститьют, Инк. Ингибиторы факторов транскрипции и их применение
JP6637884B2 (ja) 2013-11-08 2020-01-29 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ブロモドメインおよびエクストラターミナル（ｂｅｔ）タンパク質インヒビターを使用するがんのための併用療法
WO2015117087A1 (fr) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Utilisations des dérivés de diazépane
BR112016017045A2 (pt) 2014-01-31 2017-08-08 Dana Farber Cancer Inst Inc Derivados de diazepano e usos dos mesmos
WO2015117053A1 (fr) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Dérivés de diaminopyrimidine benzènesulfone et leurs utilisations
CN106456653A (zh) 2014-02-28 2017-02-22 腾沙治疗公司 高胰岛素血症相关病症的治疗
MX2017001757A (es) 2014-08-08 2017-05-30 Dana Farber Cancer Inst Inc Derivados de dihidropteridinona y sus usos.
KR20170032473A (ko) 2014-08-08 2017-03-22 다나-파버 캔서 인스티튜트 인크. 디아제판 유도체 및 그의 용도
AU2015339511B2 (en) 2014-10-27 2020-05-14 Tensha Therapeutics, Inc. Bromodomain inhibitors
EP3307728A4 (fr) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
WO2017044792A1 (fr) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Acétamide thiénotriazoldiazépines et leurs utilisations
WO2017044849A1 (fr) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Cyano-thiénotriazoloazépines et leurs utilisations
SG11201803210YA (en) 2015-11-25 2018-05-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
CN111225915B (zh) * 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1314191B1 (it) 1999-10-18 2002-12-06 Recordati Chem Pharm Derivati isossazolcarbossamidici
WO2002002557A2 (fr) * 2000-06-30 2002-01-10 Neurogen Corporation Derives imidazo[1,2-a]pyridine 2-substitues
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
US6596731B2 (en) * 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
GB0108475D0 (en) * 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
PL366624A1 (en) 2001-07-05 2005-02-07 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as mch selective antagonists
GB0212048D0 (en) * 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
AU2003261834A1 (en) * 2002-08-30 2004-05-04 Bf Research Institute, Inc. Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
WO2004076452A1 (fr) * 2003-02-26 2004-09-10 Merck Sharp & Dohme Limited 5,8-difluoroimidazo[1,2-a]pyridines constituant des ligands gaba-a ?2/?3 utilises dans le traitement de l'anxiete et/ou de la depression
WO2005123672A2 (fr) 2004-06-14 2005-12-29 Takeda San Diego, Inc. Inhibiteurs de kinase

Also Published As

Publication number Publication date
EP1979350A1 (fr) 2008-10-15
TW200736257A (en) 2007-10-01
RU2008126807A (ru) 2010-02-27
IL192636A0 (en) 2009-02-11
KR101062583B1 (ko) 2011-09-06
KR20080075924A (ko) 2008-08-19
US20070179178A1 (en) 2007-08-02
JP4913157B2 (ja) 2012-04-11
RU2426732C2 (ru) 2011-08-20
AU2007207053B2 (en) 2012-05-24
CA2636112A1 (fr) 2007-07-26
WO2007082806A1 (fr) 2007-07-26
US7585874B2 (en) 2009-09-08
BRPI0706560A2 (pt) 2011-03-29
CN101370807A (zh) 2009-02-18
AR059016A4 (es) 2008-03-05
NO20082956L (no) 2008-08-06
JP2009523752A (ja) 2009-06-25
AU2007207053A1 (en) 2007-07-26
CN101370807B (zh) 2011-08-31
TWI338691B (en) 2011-03-11

Similar Documents

Publication Publication Date Title
ZA200805839B (en) Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of Alzheimer's disease via GABA receptors
DK3872058T3 (en) Process for the preparation of 2,3,3,3 tetrahydrofluoropropene
EP1940373B8 (fr) 1-fluoro-1-deoxy-scyllo-inositol destine au traitement de la maladie d'alzheimer
ZA200808178B (en) Imidazolothiazole compounds for the treatment of disease
PL1993985T3 (pl) Sposób wytwarzania 1,2-propanodiolu
ZA200706791B (en) Isoxazole combretasin derivatives for the treatment of disorders
IL204693A0 (en) Imidazo[1, 2 - a] pyrimidine derivatives for the treatment of diseases such as diabetes
IL188165A0 (en) Method for the diagnosis of alzheimer's disease
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
EP2063889A4 (fr) Inhibiteurs de la spiropipéridine bêta-sécrétase pour le traitement de la maladie d'alzheimer
ZA200809857B (en) Terphenyl derivatives for treatment of alzheimer's disease
ZA200909191B (en) Catecholamine derivatives useful for the treatment of parkinson's disease
ZA200809284B (en) Polymorph forms of (2S) - (4E) -N-Methyl-5- )3-Isopropoxypyridin) YL]-4-Penten-2-amine for the treatment of central nervous system disorders
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
EP1858499A4 (fr) Methodes de traitement de maladie degenerative retinienne
IL205156A0 (en) (1,4-diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone ligands for nicotinic acetylcholine receptors, useful for the treatment of disease
EP1768656A4 (fr) Traitement de maladies oculaires
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
EP2083003A4 (fr) Procédé de préparation de 1,1,1,3,3-pentachlorobutane
EP1996192A4 (fr) Procede de preparation de thiazolidin-2-ones bi-substitues en 3,4
GB0400802D0 (en) Compounds for the treatment of disease
EP2305629A4 (fr) Agent thérapeutique pour la maladie d'alzheimer
EP1863510A4 (fr) Méthodes de traitement de la maladie de parkinson
EP2099476A4 (fr) Procédés de traitement de maladie d'alzheimer
ZA200907251B (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease